Enhertu approved in US for breast cancer post more endocrine therapies
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
The company remains focused on strengthening its direct retail presence and expanding its reach to more customers across India.
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
Subscribe To Our Newsletter & Stay Updated